GU Cancers 2024 | Treatment outcomes in primary retroperitoneal germ-cell tumours

Patrizia Giannatempo, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, provides findings from the PRIMERE study, a retrospective analysis which addresses the challenges posed by primary retroperitoneal germ cell tumors (pR-GCT). Most patients evaluated underwent cisplatin-based chemotherapy (BEP regimen) and despite challenges in diagnosing primary testicular tumors, approximately half of patients achieved a 5-year overall survival (OS). The role of radical orchiectomy and the potential existence of a distinct p-GCT category additionally warrant further exploration. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.